Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale ...

Graham G. Walmsley, a director at Akero Therapeutics, Inc. (NASDAQ:AKRO), recently acquired a significant amount of the company's common stock. According to a recent SEC filing, Walmsley purchased 200 ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...

NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...